Application of “Betargin” in complex treatment of patients with the first diagnostic tubercolosis with toxic complications of antituburculosis therapy
The aim of the work is to evaluate the effect of “Betargin” on the dynamics of clinical and biochemical parameters and to determine the feasibility of its use in patients with toxic side-effects for the treatment of tuberculosis with a clear toxicity syndrome. 38 patients with tuberculosis with toxic complications of chemotherapy were examined. Patients of the control group (CG) (20 persons) received standard antituberculous treatment. Patients of the main group (MG) (18 persons) received the agent “Betargin” in addition to this therapy. Evaluated clinical and laboratory parameters (blood test, levels of ALT, AST, bilirubin, total protein of blood). Manifestations of toxic adverse reactions in both groups have decreased. The dynamics of regression of complications of polychemotherapy was higher in MG patients. In 15 (83.0 %) patients with MG and 10 (50.0 %) of MG manifestations decreased, and in 13 (72.0 %) and 7 (35.0 %) respectively, the toxicity syndrome completely disappeared (p<0,05). Drowsiness decreased or disappeared in 14 (77.8 %) and 8 (40.0 %) patients respectively, increased fatigue — in 12 (66.7 %) and 3 (15.0 %). The levels of ALT and AST in MG by therapy decreased significantly (p<0,05) by 77.8 % and 61.1 % respectively; in CG the decreasing in these rates was less clear and was 35.0 % (ALT) and 15.0 % (AST). So, “Betargin” quickly eliminates the manifestations of astenovegetative and intoxication syndrome in the underlying disease, minimizes discomfort, improves appetite and general condition of patients. The use of “Betargin” in patients with tuberculosis improves clinical parameters, as well as data from laboratory and clinical research methods. The use of “Betargin” does not require the abolition of major anti-TB drugs, but is used in combination with them.
2. Zakon Ukrainy vid 16 zhovtnia 2012 № 5451 VI “Kontseptsiia Zahalnoderzhavnoi prohramy protydii zakhvoriuvanniu na tuberkuloz na 2012–2016 roky”. [in Ukrainian].
3. Melnyk, V. M. (2011). Epidemiolohichna sytuatsiia z tuberkulozu v Ukraini ta efektyvnist likuvannia khvorykh na tuberkuloz, Materialy V zizdu ftyziatriv i pulmonolohiv Ukrainy. [in Ukrainian].
4. Moskalenko, V. F., Petrenko, V. I., Protsiuk, R. H. & Donets, D. H. (2010). Tuberkuloz — aktualna problema v Ukraini. Tuberkuloz, lehenevi khvoroby, VIL-infektsiia, 1, 18–17. [in Ukrainian].
5. Moskalenko, V. F., Petrenko, V. I. & Timoshenko, G. A. (2012). Ftiziatriya: uchebnoe posobie. Kiev: Medicina. [in Russian].
6. Protsiuk, R. H. & Petrenko, V. I. (2015). Problema tuberkulozu v Ukraini. Tuberkuloz, lehenevi khvoroby, VIL-infektsiia, 2, 16–17. [in Ukrainian].
7. Protsiuk, R. H. (2010). Suchasni problemy epidemii tuberkulozu v Ukraini: prychyny i shliakhy yii podolannia. Zdorovia Ukrainy, 63–66. [in Ukrainian].
8. Feshchenko, Yu. I., Cherenko, S. O. & Matvieieva, O. V. (2014). Pobichni reaktsii protytuberkuloznykh preparativ u protsesi otsinky naslidkiv likuvannia khvorykh na tuberkuloz. Tuberkuloz, lehenevi khvoroby, VIL-infektsiia, 4, 13–19. [in Ukrainian].
9. World Health Organization. (2012). Global tuberculosis Control report. WHO report. Gevena, Switzerland, 273.
10. Zhang, Y. & Yew, W. W. (2010). Mechanisms of drug resistance in Mycobacterium tuberculosis. Drug-resistant tuberculosis. Int. J. Tuberc. Lung Dis., 13 (11), 1320–1330.